留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肌腱蛋白-C在肝移植术后早期急性排斥反应中的作用

曹薇薇 杨佩军 李霄

曹薇薇, 杨佩军, 李霄. 肌腱蛋白-C在肝移植术后早期急性排斥反应中的作用[J]. 器官移植, 2021, 12(3): 288-293. doi: 10.3969/j.issn.1674-7445.2021.03.006
引用本文: 曹薇薇, 杨佩军, 李霄. 肌腱蛋白-C在肝移植术后早期急性排斥反应中的作用[J]. 器官移植, 2021, 12(3): 288-293. doi: 10.3969/j.issn.1674-7445.2021.03.006
Cao Weiwei, Yang Peijun, Li Xiao. Role of tenascin-C in acute rejection early after liver transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 288-293. doi: 10.3969/j.issn.1674-7445.2021.03.006
Citation: Cao Weiwei, Yang Peijun, Li Xiao. Role of tenascin-C in acute rejection early after liver transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 288-293. doi: 10.3969/j.issn.1674-7445.2021.03.006

肌腱蛋白-C在肝移植术后早期急性排斥反应中的作用

doi: 10.3969/j.issn.1674-7445.2021.03.006
基金项目: 

国家自然科学基金 81970566

国家自然科学基金 81670593

国家自然科学基金 81671838

国家自然科学基金 81870446

国家自然科学基金 82070681

陕西省自然科学基础研究计划 2017JM8014

安康职业技术学院院级科学研究项目 AZJKY2020027

详细信息
    作者简介:

    曹薇薇,女,硕士,讲师,研究方向为检验医学基础与临床研究,Email: caoweiwei0408@163.com

    通讯作者:

    李霄,男,博士,研究方向为普通外科基础与临床研究,Email: lixiao0076@163.com

  • 中图分类号: R617

Role of tenascin-C in acute rejection early after liver transplantation

More Information
  • 摘要:   目的  探讨肌腱蛋白-C(TNC)与肝移植术后早期急性排斥反应(AR)的关系。  方法  将6只Brown Norway(BN)大鼠和16只Lewis大鼠分为AR组(Lewis→BN,供、受体各6只)和对照组(Lewis→Lewis,供、受体各5只)。对两组大鼠移植肝组织进行病理学检查,采用Banff分级评估排斥活动指数(RAI);采用免疫组织化学(免疫组化)染色、蛋白质印迹法检测两组大鼠移植肝TNC蛋白表达情况;采用酶联免疫吸附试验(ELISA)检测血清TNC表达水平,并分析其与RAI评分的相关性。  结果  大鼠肝移植术后7 d移植肝病理学结果显示AR组RAI评分高于对照组;免疫组化结果显示术后7 d AR组移植肝TNC阳性细胞分布多于对照组;蛋白质印迹法结果显示术后7 d AR组移植肝TNC蛋白相对表达量高于对照组(t=5.112,P=0.007);ELISA结果显示术后7 d AR组血清TNC表达水平高于对照组(t=3.152,P=0.012),且血清TNC表达水平与RAI评分呈正相关(r=0.790 9,P=0.004)。  结论  肝移植术后TNC表达水平与AR相关,TNC有可能成为临床肝移植术后早期AR诊断和治疗的新靶点。

     

  • 图  1  两组大鼠移植肝组织病理学表现(HE,×200)

    注:A图为对照组;B图为AR组。

    Figure  1.  Pathological findings of liver allograft tissuesof rats in two groups

    图  2  两组大鼠移植肝组织TNC阳性细胞分布情况(免疫组化,×200)

    注:A图为对照组;B图为AR组。

    Figure  2.  Distribution of TNC positive cells of liver allograft tissues of rats in two groups

    图  3  两组大鼠移植肝组织TNC蛋白相对表达量

    注:A图为两组大鼠移植肝组织蛋白质印迹图片;B图为两组大鼠移植肝组织TNC蛋白相对表达量的比较,与对照组比较,aP < 0.05。

    Figure  3.  Relative protein expression level of TNC of liver allograft tissues of rats in two groups

    图  4  两组大鼠肝移植术后血清TNC表达水平及与RAI评分的相关性

    注:A图示两组大鼠肝移植术后7 d血清TNC表达水平,与对照组比较,aP < 0.05;B图示大鼠肝移植术后7 d血清TNC表达水平与RAI评分的相关性。

    Figure  4.  Expression level of TNC in serum after liver transplantation and its correlation with RAI score of rats in two groups

  • [1] 沈中阳. 中国肝移植的发展与创新[J]. 临床肝胆病杂志, 2019, 35(11): 2377-2385. DOI: 10.3969/j.issn.1001-5256.2019.11.001.

    SHEN ZY. Development and innovation of liver transplantation in China[J]. J Clin Hepatol, 2019, 35(11): 2377-2385. DOI: 10.3969/j.issn.1001-5256.2019.11.001.
    [2] 石炳毅. 继往开来, 中国器官移植的发展现状——在2018年中华医学会器官移植学年会上的报告[J]. 器官移植, 2019, 10(1): 32-35. DOI: 10.3969/j.issn.1674-7445.2019.01.004.

    SHI BY. Development status of organ transplantation in China: the report on the 2018 Annual Meeting of Organ Transplantation of Chinese Medical Association[J]. Organ Transplant, 2019, 10(1): 32-35. DOI: 10.3969/j.issn.1674-7445.2019.01.004.
    [3] 卢中山, 王伟, 钟自彪, 等. 肝脏缺血再灌注损伤干预措施的研究进展[J]. 中华肝胆外科杂志, 2019, 25(11): 871-874. DOI: 10.3760/cma.j.issn.1007-8118.2019.11.020.

    LU ZS, WANG W, ZHONG ZB, et al. Advances in intervention measures for hepatic ischemia-reperfusion injury[J]. Chin J Hepatobiliary Surg, 2019, 25(11): 871-874. DOI: 10.3760/cma.j.issn.1007-8118.2019.11.020.
    [4] ALLISON SJ. Nanosensors enable early detection of acute T cell-mediated rejection of transplants[J]. Nat Rev Nephrol, 2019, 15(5): 253. DOI: 10.1038/s41581-019-0134-7.
    [5] TONIUTTO P, ZANETTO A, FERRARESE A, et al. Current challenges and future directions for liver transplantation[J]. Liver Int, 2017, 37(3): 317-327. DOI: 10.1111/liv.13255.
    [6] BENSELER V, MCCAUGHAN GW, SCHLITT HJ, et al. The liver: a special case in transplantation tolerance[J]. Semin Liver Dis, 2007, 27(2): 194-213. DOI: 10.1055/s-2007-979471.
    [7] ABU-GAZALA S, OLTHOFF KM. Status of adult living donor liver transplantation in the United States: results from the adult-to-adult living donor liver transplantation cohort study[J]. Gastroenterol Clin North Am, 2018, 47(2): 297-311. DOI: 10.1016/j.gtc.2018.01.004.
    [8] CHARLTON M, LEVITSKY J, AQEL B, et al. International Liver Transplantation Society consensus statement on immunosuppression in liver transplant recipients[J]. Transplantation, 2018, 102(5): 727-743. DOI: 10.1097/TP.0000000000002147.
    [9] VON PLATEN A, D'SOUZA MA, ROOYACKERS O, et al. Intrahepatic microdialysis for monitoring of metabolic markers to detect rejection early after liver transplantation[J]. Transplant Proc, 2020, 53(1): 130-135. DOI: 10.1016/j.transproceed.2020.02.157.
    [10] BABA HA, THEURER S, CANBAY A, et al. Liver transplantation. current aspects of pretransplantation diagnosis and rejection[J]. Pathologe, 2020, 41(5): 505-514. DOI: 10.1007/s00292-020-00813-9.
    [11] TUCKER RP, CHIQUET-EHRISMANN R. Tenascin-C: its functions as an integrin ligand[J]. Int J Biochem Cell Biol, 2015, 65: 165-168. DOI: 10.1016/j.biocel.2015.06.003.
    [12] LOWY CM, OSKARSSON T. Tenascin C in metastasis: a view from the invasive front[J]. Cell Adh Migr, 2015, 9(1/2): 112-124. DOI: 10.1080/19336918.2015.1008331.
    [13] TANABE S, UEDA M, HAN YS, et al. Increased tenascin expression is an early feature of the development of transplant renal arteriopathy in humans[J]. Transpl Int, 1996, 9(Suppl 1): S45-S48. DOI: 10.1007/978-3-662-00818-8_13.
    [14] CHEN S, FU H, WU S, et al. Tenascin-C protects against acute kidney injury by recruiting Wnt ligands[J]. Kidney Int, 2019, 95(1): 62-74. DOI: 10.1016/j.kint.2018.08.029.
    [15] KAMADA N. The immunology of experimental liver transplantation in the rat[J]. Immunology, 1985, 55(3): 369-389.
    [16] ROUFOSSE C, SIMMONDS N, CLAHSEN-VAN GRONINGEN M, et al. A 2018 reference guide to the Banff classification of renal allograft pathology[J]. Transplantation, 2018, 102(11): 1795-1814. DOI: 10.1097/TP.0000000000002366.
    [17] AGOPIAN VG, HARLANDER-LOCKE MP, MARKOVIC D, et al. Evaluation of early allograft function using the liver graft assessment following transplantation risk score model[J]. JAMA Surg, 2018, 153(5): 436-444. DOI: 10.1001/jamasurg.2017.5040.
    [18] KRENZIEN F, KESHI E, SPLITH K, et al. Diagnostic biomarkers to diagnose acute allograft rejection after liver transplantation: systematic review and Meta-analysis of diagnostic accuracy studies[J]. Front Immunol, 2019, 10: 758. DOI: 10.3389/fimmu.2019.00758.
    [19] KOK B, DONG V, KARVELLAS CJ. Graft dysfunction and management in liver transplantation[J]. Crit Care Clin, 2019, 35(1): 117-133. DOI: 10.1016/j.ccc.2018.08.002.
    [20] KOHUT TJ, BARANDIARAN JF, KEATING BJ. Genomics and liver transplantation: genomic biomarkers for the diagnosis of acute cellular rejection[J]. Liver Transpl, 2020, 26(10): 1337-1350. DOI: 10.1002/lt.25812.
    [21] RODRIGO E, CHEDID MF, SEGUNDO DS, et al. Acute rejection following kidney transplantation: state-of-the-art and future perspectives[J]. Curr Pharm Des, 2020, 26(28): 3468-3496. DOI: 10.2174/1381612826666200610184433.
    [22] 王朝阳, 朱美意, 欧阳军, 等. Neuritin与HSP60在急性肝损伤修复中的表达变化及意义[J]. 实用医学杂志, 2018, 34(12): 1959-1964, 1969. DOI: 10.3969/j.issn.1006-5725.2018.12.010.

    WANG CY, ZHU MY, OUYANG J, et al. Expression and significance of Neuritin and HSP60 in repair of acute liver injury[J]. J Pract Med, 2018, 34(12): 1959-1964, 1969. DOI: 10.3969/j.issn.1006-5725.2018.12.010.
    [23] WEI Q, WANG K, YANG M, et al. Recipient gender and body mass index are associated with early acute rejection in donation after cardiac death liver transplantation[J]. Clin Res Hepatol Gastroenterol, 2020, 44(Suppl): 100004. DOI: 10.1016/j.clirex.2020.100004.
    [24] MARZEDA AM, MIDWOOD KS. Internal affairs: tenascin-C as a clinically relevant, endogenous driver of innate immunity[J]. J Histochem Cytochem, 2018, 66(4): 289-304. DOI: 10.1369/0022155418757443.
    [25] CHIQUET M. Tenascin-C: from discovery to structure-function relationships[J]. Front Immunol, 2020, 11: 611789. DOI: 10.3389/fimmu.2020.611789.
    [26] BENBOW JH, ELAM AD, BOSSI KL, et al. Analysis of plasma tenascin-C in post-HCV cirrhosis: a prospective study[J]. Dig Dis Sci, 2018, 63(3): 653-664. DOI: 10.1007/s10620-017-4860-z.
    [27] BENBOW JH, THOMPSON KJ, COPE HL, et al. Diet-induced obesity enhances progression of hepatocellular carcinoma through tenascin-C/Toll-like receptor 4 signaling[J]. Am J Pathol, 2016, 186(1): 145-158. DOI: 10.1016/j.ajpath.2015.09.015.
    [28] KURIYAMA N, DUARTE S, HAMADA T, et al. Tenascin-C: a novel mediator of hepatic ischemia and reperfusion injury[J]. Hepatology, 2011, 54(6): 2125-2136. DOI: 10.1002/hep.24639.
    [29] MOMČILOVIĆ M, STAMENKOVIĆ V, JOVANOVIĆ M, et al. Tenascin-C deficiency protects mice from experimental autoimmune encephalomyelitis[J]. J Neuroimmunol, 2017, 302: 1-6. DOI: 10.1016/j.jneuroim.2016.12.001.
    [30] ZHAO YY, LOU L, YANG KC, et al. Correlation of tenascin-C concentrations in serum with outcome of traumatic brain injury in humans[J]. Clin Chim Acta, 2017, 472: 46-50. DOI: 10.1016/j.cca.2017.07.018.
  • 加载中
图(6)
计量
  • 文章访问数:  274
  • HTML全文浏览量:  88
  • PDF下载量:  40
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-02-15
  • 网络出版日期:  2021-05-19
  • 刊出日期:  2021-05-15

目录

    /

    返回文章
    返回